On Tuesday, Shattuck Labs (NASDAQ: STTK) experienced a shift in stock rating, following the company's decision to change its research and development focus. H.C. Wainwright has downgraded the biotechnology firm from Buy to Neutral after the company announced it would no longer continue developing its SL-17254 drug for hematologic malignancies.
The company made the strategic decision after reviewing its pipeline and the data accumulated on CD47 in blood cancers. Shattuck Labs has decided to reallocate resources away from SL-17254 in higher-risk myelodysplastic syndromes (HR-MDS) or TP53+ acute myeloid leukemia (AML). Although the latest data showed some incremental benefits in overall response rate (ORR) and median overall survival (mOS) compared to control, the combination of SL-172154 with azacitidine (AZA) did not demonstrate a significant enough benefit to justify further development.
The move comes as a disappointment given the positive nature of the data, but the current skepticism surrounding the CD47 space in oncology and investor wariness has made the path forward challenging. Shattuck Labs is now refocusing on an autoimmune-focused pipeline, which is still in the early stages of development. The firm's pivot to this new area of research has prompted the analyst to adopt a wait-and-see approach, downgrading the stock to Neutral until there is more clarity on the clinical development of these new assets.
In other recent news, Shattuck Labs also terminated a collaboration agreement with Ono Pharmaceutical Co., which will not affect the development of SL-325. The company's SL-172154 had previously received an orphan drug designation from the U.S. Food and Drug Administration, potentially accelerating the drug's development.
InvestingPro Insights
In light of Shattuck Labs' strategic shift, InvestingPro data provides additional context to the company's financial situation. With a market capitalization of $94.5 million, STTK's revenue for the last twelve months as of Q2 2024 stood at $4.12 million, showing a remarkable revenue growth of 380.09% over the same period. This growth aligns with one of the InvestingPro Tips, which indicates that analysts anticipate sales growth in the current year.
However, the company's financial health presents some challenges. An InvestingPro Tip highlights that STTK is quickly burning through cash, which is particularly relevant given the company's recent decision to reallocate resources. This cash burn rate could be a critical factor as Shattuck Labs pivots to its autoimmune-focused pipeline.
Another InvestingPro Tip notes that the stock price movements are quite volatile, which is evident in the 129.61% price return over the past year, contrasted with a -60.74% return over the last six months. This volatility underscores the market's reaction to the company's strategic decisions and the uncertainty surrounding its new research direction.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips that could provide deeper insights into Shattuck Labs' financial outlook and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.